Allergy Therapeutics Market Cap ($1.00 Million)
Market Cap & Net Worth: Allergy Therapeutics (AGY)
Allergy Therapeutics market cap. Allergy Therapeutics (LSE:AGY) has a market capitalization of $1.00 Million (GBX8.23 Billion) as of November 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30662 globally and #813 in its home market, demonstrating a -67.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Allergy Therapeutics's stock price GBX1.30 by its total outstanding shares 6332529550 (6.33 Billion). Also see Allergy Therapeutics cash flow conversion for how efficiently the company converts equity into cash flow.
Allergy Therapeutics Market Cap History (2015–2026)
Allergy Therapeutics market cap history from 2015 to 2026. Data shows change from $22.73 Million to $1.00 Million (-24.34% CAGR). Check today's stock price for Allergy Therapeutics for real-time trading data and today's change.
Index Memberships
Allergy Therapeutics is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$992.58 Million | 0.10% | #160 of 722 |
Weight: Allergy Therapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Allergy Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Allergy Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Allergy Therapeutics (AGY) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.15x
Allergy Therapeutics's market cap is 0.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $16.08 Million | $48.51 Million | -$13.07 Million | 0.33x | N/A |
| 2017 | $21.96 Million | $64.14 Million | -$2.48 Million | 0.34x | N/A |
| 2018 | $10.50 Million | $68.35 Million | -$7.53 Million | 0.15x | N/A |
| 2019 | $7.90 Million | $73.72 Million | $3.47 Million | 0.11x | 2.28x |
| 2020 | $12.81 Million | $78.20 Million | $7.06 Million | 0.16x | 1.81x |
| 2021 | $25.43 Million | $84.33 Million | $2.89 Million | 0.30x | 8.81x |
| 2022 | $4.82 Million | $72.77 Million | -$13.78 Million | 0.07x | N/A |
| 2023 | $1.93 Million | $59.59 Million | -$43.07 Million | 0.03x | N/A |
| 2024 | $5.01 Million | $55.20 Million | -$40.22 Million | 0.09x | N/A |
| 2025 | $8.48 Million | $55.04 Million | -$40.13 Million | 0.15x | N/A |
Competitor Companies of AGY by Market Capitalization
Companies near Allergy Therapeutics in the global market cap rankings as of November 7, 2026. Also see Allergy Therapeutics asset portfolio for a full breakdown of the balance sheet.
Key companies related to Allergy Therapeutics by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #506 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #532 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #570 globally with a market cap of $46.85 Billion USD ( CN¥320.16 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #615 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #506 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #532 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.40 |
| #570 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.85 Billion | CN¥50.19 |
| #615 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €19.30 |
Market Capitalization of Allergy Therapeutics (2015–2026)
Market capitalization of Allergy Therapeutics from 2015 to today. Between 2015 and today, Allergy Therapeutics's market cap moved from $22.73 Million to $ 1.00 Million, with a yearly change of -24.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX1.00 Million | -88.18% |
| 2025 | GBX8.48 Million | +69.23% |
| 2024 | GBX5.01 Million | +160.00% |
| 2023 | GBX1.93 Million | -60.00% |
| 2022 | GBX4.82 Million | -81.06% |
| 2021 | GBX25.43 Million | +98.50% |
| 2020 | GBX12.81 Million | +62.20% |
| 2019 | GBX7.90 Million | -24.77% |
| 2018 | GBX10.50 Million | -52.19% |
| 2017 | GBX21.96 Million | +36.53% |
| 2016 | GBX16.08 Million | -29.24% |
| 2015 | GBX22.73 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Allergy Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.00 Million USD |
| MoneyControl | $1.00 Million USD |
| MarketWatch | $1.00 Million USD |
| marketcap.company | $1.00 Million USD |
| Reuters | $1.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more